CJC-1295 vs Tesamorelin: Literature and Handling Compared
Two compounds, two separate research records. This reference sets CJC-1295 and Tesamorelin against each other on parameters a laboratory can independently verify.
Compound profiles
CJC-1295 in the indexed record
Indexed output for CJC-1295 stands at 33 records, a limited literature, alongside 1 registered studies on ClinicalTrials.gov.
Publications carrying this compound include Am J Sports Med, Growth Horm IGF Res, J Am Acad Orthop Surg Glob Res Rev, spanning 2006–2026.
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults — J Clin Endocrinol Metab, 2006. PMID: 16352683
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians — Am J Sports Med, 2026. PMID: 41476424
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — J Am Acad Orthop Surg Glob Res Rev, 2026. PMID: 41490200
- Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions — Subst Use Misuse, 2016. PMID: 26771670
Tesamorelin in the indexed record
Searching Tesamorelin against the PubMed index returns 121 records, a moderate evidence base, alongside 24 registered studies on ClinicalTrials.gov.
Recent indexed work appears in Ann Pharmacother, BETA, Curr Opin Investig Drugs, spanning 2006–2012.
- Tesamorelin — , 2012. PMID: 31644039
- Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy — Ann Pharmacother, 2012. PMID: 22298602
- Tesamorelin, a human growth hormone releasing factor analogue — Expert Opin Investig Drugs, 2009. PMID: 19243281
- Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy — Drugs, 2011. PMID: 21668043
Side-by-side research profile
| Parameter | CJC-1295 | Tesamorelin |
|---|---|---|
| PubMed indexed records | 33 | 121 |
| Registered studies (ClinicalTrials.gov) | 1 | 24 |
| Literature depth | Emerging | Moderate |
| Handling class | Lyophilised powder | Lyophilised powder |
| Designation | Research use only | Research use only |
Classification and why it matters
CJC-1295 and Tesamorelin sit in different structural classes, and that classification is what determines whether a published protocol for one has any bearing on the other. Peptide research compounds are grouped by sequence length, origin and the receptor families the literature associates with them — not by the outcome a reader might be looking for.
Reading across classes is the most common error in a literature review. A protocol developed for CJC-1295 describes conditions validated for CJC-1295: concentration ranges, solvent choice, incubation windows and control selection were all established against that compound. Applying those same conditions to Tesamorelin without re-validation produces data that cannot be compared back to the source publication.
Where the two compounds are studied in overlapping models, the published work almost always treats them as separate arms rather than as substitutes. That separation is the useful signal: it indicates the research record does not consider them equivalent.
How the literature differs
The indexed record is not symmetrical between these two compounds. Tesamorelin carries 88 more indexed records than CJC-1295, which means published methodology, characterisation data and replication attempts are more readily located for Tesamorelin. For a researcher planning a literature review, that asymmetry usually determines which compound has established reference protocols and which requires primary-source work.
Registered study counts (1 vs 24) track a different signal — formal study registration rather than published output — and the two figures frequently diverge.
Selecting between them for a study design
CJC-1295 and Tesamorelin are not interchangeable. They differ in structural class and in the pathways the literature associates with each, so substituting one for the other changes what a model is actually measuring.
Where a protocol cites a specific compound, the cited compound is the one the published result applies to. Where no protocol exists, the compound with the deeper indexed record (Tesamorelin) generally offers more methodological precedent.
Verification and documentation
What is in the vial is established by lot-specific analytics, not by label text. HPLC gives purity as a share of total peak area; mass spectrometry confirms the molecular weight matches the intended sequence. Neither substitutes for the other.
Frequently asked questions
What is the regulatory status of these compounds?
Neither is an approved drug. Both are supplied strictly for in-vitro laboratory research and are not intended for human or veterinary consumption.
How should these compounds be stored?
Lyophilised material is conventionally stored at -20°C protected from light. Reconstituted solution is far less stable and is held at 2-8°C for short-duration laboratory work only.
Are CJC-1295 and Tesamorelin the same compound?
No. They are structurally distinct research compounds with separate literature records — 33 indexed records for CJC-1295 and 121 for Tesamorelin.
Related references
- CJC-1295 — product and lot documentation
- Tesamorelin — product and lot documentation
- Certificate of analysis & purity testing
- Research reference index
Research use only. The compounds discussed are supplied for in-vitro laboratory research. They are not drugs, are not approved for the diagnosis, treatment, cure or prevention of any condition, and are not intended for human or veterinary consumption.